Risk of subsequent melanoma after melanoma in situ and invasive melanoma: A population-based study from 1973 to 2011 - 17/04/15
, David Huang, BS a, b, Martin A. Weinstock, MD, PhD a, b, c, dAbstract |
Background |
Patients with melanoma in situ are at an increased risk of subsequent melanoma compared with the general population, but the risk of subsequent melanoma after initial melanoma in situ versus after initial invasive melanoma is not known.
Objective |
We sought to compare the risk of subsequent melanoma in the cohort whose first cancer was melanoma in situ to the risk in the cohort whose first cancer was invasive melanoma.
Methods |
In this cohort study, we identified individuals whose first cancer was either melanoma in situ or invasive melanoma from the Surveillance, Epidemiology, and End Results (SEER) program between 1973 and 2011 and used Cox proportional hazards models for comparison.
Results |
Compared with the invasive melanoma cohort, the melanoma in situ cohort was more likely to develop subsequent melanoma of any stage after 2 years, subsequent invasive melanoma after 10 years, and subsequent melanoma in situ at all the time points (P < .001, P = .003, P < .001, respectively).
Limitations |
Underreporting of melanomas, particularly melanoma in situ cases, and missing cases of subsequent melanomas as a result of patient migration from the SEER registry areas could affect results.
Conclusion |
Given the increased long-term risk of subsequent melanoma in the melanoma in situ cohort, the patients with melanoma in situ diagnosis may benefit from a long-term surveillance for subsequent melanomas.
Le texte complet de cet article est disponible en PDF.Key words : invasive melanoma, melanoma, melanoma in situ, risk comparisons, Surveillance, Epidemiology, and End Results, subsequent melanoma
Abbreviations used : CI, HR, SEER
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 72 - N° 5
P. 794-800 - mai 2015 Retour au numéro
Article précédent
- Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma
- Marius Ilie, Elodie Long-Mira, Elisa Funck-Brentano, Sandra Lassalle, Catherine Butori, Virginie Lespinet-Fabre, Olivier Bordone, Alexandre Gay, Katia Zahaf, Gilles Poissonnet, Jean-Philippe Lacour, Philippe Bahadoran, Robert Ballotti, Audrey Gros, Caroline Dutriaux, Philippe Saiag, Jean-Philippe Merlio, Béatrice Vergier, Jean François Emile, Véronique Hofman, Paul Hofman
- Age, gender, and topography influence the clinical and dermoscopic appearance of lentigo maligna
- Danica Tiodorovic-Zivkovic, Giuseppe Argenziano, Aimilios Lallas, Luc Thomas, Aleksandra Ignjatovic, Harold Rabinovitz, Elvira Moscarella, Caterina Longo, Rainer Hofmann-Wellenhof, Iris Zalaudek
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?